Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD

Ekaterina Kim, Shih-Shih Chen, Mariela Sivina, Hyunsoo Hwang, Xuelin Huang, Alessandra Ferrajoli, Nitin Jain, William G. Wierda, Dominik Wodarz, Nicholas Chiorazzi, Jan A. Burger

Blood blood.2024025683.

https://doi.org/10.1182/blood.2024025683

Published: 2024

Includes: Supplemental data

Journal Articles

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase 2 Trial

Jan A. Burger, Ekaterina Kim, Mariela Sivina, Thomas Mathew, Danielle E. Hammond, Fadi G. Haddad, Alessandra Ferrajoli, William G. Wierda

Blood (2023) 142 (Supplement 1): 6524.

https://doi.org/10.1182/blood-2023-178774

Published: 2023

Journal Articles

High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)

Ekaterina Kim, Mariela Sivina, Alicia Vaca, Alessandra Ferrajoli, Nitin Jain, Philip A. Thompson, William G. Wierda, Dominik Wodarz, Nicholas Chiorazzi, Jan A. Burger

Blood (2022) 140 (Supplement 1): 4140–4141.

https://doi.org/10.1182/blood-2022-160238

Published: 2022

Journal Articles

Changes in the T Helper Cell Compartment during Treatment with the BTK Inhibitor Acalabrutinib

Alicia Vaca, Mariela Sivina, Ekaterina Kim, Alessandra Ferrajoli, William G. Wierda, Jan A. Burger

Blood (2022) 140 (Supplement 1): 9855–9856.

https://doi.org/10.1182/blood-2022-159743

Published: 2022

Journal Articles

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations

Mariela Sivina, Ekaterina Kim, William G. Wierda, Alessandra Ferrajoli, Nitin Jain, Philip Thompson, Hagop Kantarjian, Michael Keating, Jan A. Burger

Blood (2021) 138 (24): 2589–2592.

https://doi.org/10.1182/blood.2021012315

Published: 2021

Includes: Supplemental data

Journal Articles

Expansion of T Follicular Helper Cells in NLC Co-Cultures Reinforces the Concept of Co-Evolution of CLL and Supportive T Helper Cell Clones

Alicia Vaca, Nikolaos Ioannou, Mariela Sivina, Elisavet Vlachonikola, Karen Clise-Dwyer, Ekaterina Kim, Dan Li, Qing Ma, Alessandra Ferrajoli, Zeev E. Estrov, William G. Wierda, Piers E.M. Patten, Alan G. Ramsay, Jan A. Burger

Blood (2021) 138 (Supplement 1): 3716.

https://doi.org/10.1182/blood-2021-151351

Published: 2021

Journal Articles

Long-Term Outcome of Treatment-Naïve and Relapsed/Refractory Patients with CLL and TP53 Aberrations Treated with Ibrutinib, with or without Rituximab

Mariela Sivina, Ekaterina Kim, William G. Wierda, Alessandra Ferrajoli, Nitin Jain, Philip A. Thompson, Zeev E. Estrov, Hagop Kantarjian, Michael J. Keating, Jan A. Burger

Blood (2021) 138 (Supplement 1): 3734.

https://doi.org/10.1182/blood-2021-151711

Published: 2021

Journal Articles

Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Mariela Sivina, Nitin Jain, MD, Ekaterina Kim, PhD, Tapan M. Kadia, MD, Zeev E. Estrov, MD, Maro Ohanian, DO, Michael Andreeff, MD PhD, Mathew Thomas, Philip A. Thompson, MB, MS, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS, Susan M. O'Brien, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141014

Published: 2020

Journal Articles

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Paolo Strati, Ellen J. Schlette, Luisa M. Solis Soto, Daniela E. Duenas, Mariela Sivina, Ekaterina Kim, Michael J. Keating, William G. Wierda, Alessandra Ferrajoli, Hagop Kantarjian, Zeev Estrov, Nitin Jain, Philip A. Thompson, Ignacio I. Wistuba, Jan A. Burger

Blood (2020) 135 (7): 510–513.

https://doi.org/10.1182/blood.2019003570

Published: 2020

Journal Articles

Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells

Alicia Vaca, PhD, Mariela Sivina, Karen Clise-Dwyer, PhD, Ekaterina Kim, MS, Michael J Keating, MBBS, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Dan Li, PhD, Qing Ma, PhD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 1746.

https://doi.org/10.1182/blood-2019-125827

Published: 2019

Journal Articles

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Ekaterina Kim, MS, Hongying Zhang, MD PhD, Mariela Sivina, Alicia Vaca, PhD, Philip A. Thompson, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 3051.

https://doi.org/10.1182/blood-2019-124473

Published: 2019

Journal Articles

Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients

Mariela Sivina, Gordon Duncan, MSc, Takashi Sakamoto, MD PhD, Ekaterina Kim, MS, Alicia Vaca, PhD, Elena Maria Hartmann, MD, Michael J Keating, MBBS, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Tak Mak, PhD DSc, Andreas Rosenwald, MD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 5448.

https://doi.org/10.1182/blood-2019-125716

Published: 2019

Journal Articles

The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia

Nakhle S. Saba, MD, Jade Meyers, Lorena Fontan, PhD, Ari Melnick, MD, Adrian Wiestner, MD PhD, Patricia Lobelle-Rich, Ekaterina Kim, MS, Jan A. Burger, MD PhD, Yara Mouawad, MD, Prescott L. Deininger, PhD, Francisco Socola, MD, Hana Safah, MD, Erik K Flemington, PhD

Blood (2019) 134 (Supplement_1): 1288.

https://doi.org/10.1182/blood-2019-131376

Published: 2019

Journal Articles

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Blood (2019) 133 (10): 1011–1019.

https://doi.org/10.1182/blood-2018-10-879429

Published: 2019

Includes: Supplemental data

Journal Articles

Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Paolo Strati, MD, Mariela Sivina, PhD, Ekaterina Kim, PhD, Michael J. Keating, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Zeev E. Estrov, MD, Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD

Blood (2018) 132 (Supplement 1): 1873.

https://doi.org/10.1182/blood-2018-99-111044

Published: 2018

Journal Articles

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

Blood (2018) 131 (16): 1820–1832.

https://doi.org/10.1182/blood-2017-11-817296

Published: 2018

Includes: Supplemental data

Journal Articles

Splicing Modulation Perturbs Key Survival Pathways and Sensitizes Chronic Lymphocytic Leukemia to Venetoclax Treatment

Blood (2017) 130 (Supplement 1): 264.

https://doi.org/10.1182/blood.V130.Suppl_1.264.264

Published: 2017

Journal Articles

The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors

Ekaterina Kim, PhD, Elisa Ten Hacken, PhD, Astrid Clarke, PhD, Michael J. Keating, MD, William G Wierda, MD PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Philip A Thompson, MBBS, Zeev Estrov, MD, Jan A. Burger, MD PhD

Blood (2017) 130 (Supplement 1): 3844.

https://doi.org/10.1182/blood.V130.Suppl_1.3844.3844

Published: 2017

Journal Articles

Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)

Jan A. Burger, MD PhD, Mariela Sivina, PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Ekaterina Kim, PhD, Tapan Kadia, MD, Zeev Estrov, MD, Graciela Nogueras González, Xuelin Huang, PhD, Maro Ohanian, DO, Michael Andreeff, MD PhD, Mathew Thomas, Lynette Alexander-Williams, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, William G Wierda, MD PhD, Michael J. Keating, MD

Blood (2017) 130 (Supplement 1): 427.

https://doi.org/10.1182/blood.V130.Suppl_1.427.427

Published: 2017

Journal Articles

CXCL13 (BCA-1) Plasma Levels Are a Useful Biological Marker for Disease Progression in Chronic Lymphocytic Leukemia (CLL) Patients

Mariela Sivina, PhD, Ekaterina Kim, PhD, Claire Pacelli, Michael J. Keating, MD, Alessandra Ferrajoli, MD, William G Wierda, MD PhD, Jan A. Burger, MD PhD

Blood (2017) 130 (Supplement 1): 3002.

https://doi.org/10.1182/blood.V130.Suppl_1.3002.3002

Published: 2017

NARROW

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase 2 Trial

High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)

Changes in the T Helper Cell Compartment during Treatment with the BTK Inhibitor Acalabrutinib

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations

Expansion of T Follicular Helper Cells in NLC Co-Cultures Reinforces the Concept of Co-Evolution of CLL and Supportive T Helper Cell Clones

Long-Term Outcome of Treatment-Naïve and Relapsed/Refractory Patients with CLL and TP53 Aberrations Treated with Ibrutinib, with or without Rituximab

Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients

The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

Splicing Modulation Perturbs Key Survival Pathways and Sensitizes Chronic Lymphocytic Leukemia to Venetoclax Treatment

The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors

Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)

CXCL13 (BCA-1) Plasma Levels Are a Useful Biological Marker for Disease Progression in Chronic Lymphocytic Leukemia (CLL) Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only